Zobrazeno 1 - 10 of 19 pro vyhledávání: '"Hilde A. M. Kooistra"'
1
Akademický článek
Convenience and satisfaction in direct oral anticoagulant–treated patients with atrial fibrillation
Autor: Margriet Piersma‐Wichers, Tessa Elling, Anne M. B. deVries‐Bots, Hilde A. M. Kooistra, Karina Meijer
Publikováno v: Research and Practice in Thrombosis and Haemostasis, Vol 5, Iss 6, Pp n/a-n/a (2021)
Abstract Background Direct oral anticoagulants (DOACs) are the preferred anticoagulants for thromboprophylaxis in atrial fibrillation. We aimed to identify determinants of quality of life related to DOAC treatment to optimize DOAC treatment convenien
Externí odkaz: https://doaj.org/article/31ee1293092d4a36bfdb8f99f7c18f03
Zobrazit plný text záznamu
2
Quality of life after switching from well-controlled vitamin K antagonist to direct oral anticoagulant
Autor: Jasper H A van Miert, Nic J. G. M. Veeger, Karina Meijer, Annelies Westerterp, Margriet Piersma-Wichers, Hilde A. M. Kooistra
Publikováno v: Thrombosis Research, 190, 69-75. PERGAMON-ELSEVIER SCIENCE LTD
BACKGROUND: Direct oral anticoagulants (DOAC) and vitamin K antagonists (VKA) prevent thromboembolism in atrial fibrillation (AF). DOAC have a fixed dosing regimen and obviate INR monitoring. Therefore, DOAC presumably affect quality of life (QoL) le
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8474276be46eaa90e13f76d5077a26cb
https://research.rug.nl/en/publications/36234fcc-112f-4025-b56c-3d735f3ecebf
Zobrazit plný text záznamu
3
More precise dosing of acenocoumarol for better control in patients aged above 80 years, a randomised controlled pilot study
Autor: Margriet Piersma-Wichers, Nic J. G. M. Veeger, Karina Meijer, J H A van Miert, Hilde A. M. Kooistra
Publikováno v: Thrombosis Research, 196, 536-538. PERGAMON-ELSEVIER SCIENCE LTD
INTRODUCTION: Many elderly patients are confined to treatment with vitamin K antagonists (VKA) instead of direct oral anticoagulants (DOACs). However, quality of VKA treatment declines with age. This might be caused by the lower dose requirements wit
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b81ac8ecdb4fb1ea8f914563388f823d
https://hdl.handle.net/11370/dc52c4a8-d96e-4163-9930-1f9a57783e32
Zobrazit plný text záznamu
4
CD47 Expression Defines Efficacy of Rituximab with CHOP in Non–Germinal Center B-cell (Non-GCB) Diffuse Large B-cell Lymphoma Patients (DLBCL), but Not in GCB DLBCL
Autor: Marcel Nijland, Renee Bouwstra, Janneke Willemien de Boer, Yuan He, Edwin Bremer, Christine Eulenburg, Ewa Cendrowicz, Emanuele Ammatuna, Rudolf S N Fehrmann, Gerwin Huls, Hilde A. M. Kooistra, Tom van Meerten
Publikováno v: Cancer immunology research, 7(10), 1663-1671. AMER ASSOC CANCER RESEARCH
Addition of rituximab (R) to “CHOP” (cyclophosphamide, doxorubicin, vincristine, and prednisone) chemotherapy improved outcome for diffuse large B-cell lymphoma (DLBCL) patients. Approximately 40% of patients who receive R-CHOP still succumb to d
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b805327acaf67e1d178f3d538bfcbb2e
https://doi.org/10.1158/2326-6066.cir-18-0781
Zobrazit plný text záznamu
7
Impact of Vitamin K Antagonists on Quality of Life in a Prospective Cohort of 807 Atrial Fibrillation Patients
Autor: Margriet Piersma-Wichers, Karina Meijer, Hanneke C. Kluin-Nelemans, Hilde A. M. Kooistra, Nic J. G. M. Veeger
Publikováno v: Circulation: Cardiovascular Quality and Outcomes, 9(4), 388-394. LIPPINCOTT WILLIAMS & WILKINS
Background— Vitamin K antagonists (VKA) use is challenging because of frequent blood monitoring and complex dosing. Therefore, many patients and physicians are reluctant to start VKA. However, it is unclear whether VKA use actually lowers quality o
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bd3c2746cb381eaea65e8b4603281b26
https://doi.org/10.1161/circoutcomes.115.002612
Zobrazit plný text záznamu
9
CD47 Expression Defines the Efficacy of Rituximab in Non-Germinal Center B-Cell (non-GCB) Diffuse Large B-Cell Lymphoma (DLBCL)
Autor: Renee Bouwstra, de Boer Janneke, Tom van Meerten, Edwin Bremer, Emanuele Ammatuna, Rudolf S N Fehrmann, Yuan He, Gerwin Huls, Hilde A. M. Kooistra
Publikováno v: Blood, 132(Suppl.1). AMER SOC HEMATOLOGY
CD47 is an immune-checkpoint protein that binds SIRPa on immune cells to deliver an inhibitory "don't eat me" signal. CD47 is a prominent new target in B-cell malignancies, in which CD47 antibody in combination with the CD20 antibody rituximab (R) is
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c300337e8a33e873ac8e219f26f2bb83
https://research.rug.nl/en/publications/4ef68faf-9152-4143-b303-a38664c2f812
Zobrazit plný text záznamu
10
Long-term quality of VKA treatment and clinical outcome after extreme overanticoagulation in 14,777 AF and VTE patients
Autor: Hanneke C. Kluin-Nelemans, Margriet Piersma-Wichers, Hilde A. M. Kooistra, Nakisa Khorsand, Nic J. G. M. Veeger, Karina Meijer
Publikováno v: Thrombosis and Haemostasis, 113(4), 881-890. GEORG THIEME VERLAG KG
SummaryVitamin K antagonists (VKA) are widely used in atrial fibrillation and venous thromboembolism (VTE). Their efficacy and safety depend on individual time in the therapeutic range (iTTR). Due to the variable dose-response relationship within pat
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d05ace4458c982ada83521a06d4830e1
https://doi.org/10.1160/th14-06-0537
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje